Tıp Fakültesi / Faculty of Medicine

Permanent URI for this collectionhttps://hdl.handle.net/11727/1403

Browse

Filters

2016 - 201982020 - 20225

Settings

Author: search.filters.author.Buyukkurt, NurhilalHas files: No

Search Results

Now showing 1 - 10 of 13
  • No Thumbnail Available
    Item
    Optimization of Minimal Residual Disease Detection by Multi-Color Flow Cytometry in Multiple Myeloma: 8 Colors and Beyond
    (2017) Kozanoglu, Ilknur; Buyukkurt, Nurhilal; Unver, Gulsah; Aytan, Pelin; Yeral, Mahmut; Boga, Can; Ozdogu, Hakan; 0000-0002-9580-628X; 0000-0002-5268-1210; 0000-0002-2553-7715; 0000-0002-0895-4787; 0000-0002-8902-1283; 0000-0002-9680-1958; ABC-4148-2020; AAE-1241-2021; AAE-3833-2019; AAE-1457-2021; AAD-5542-2021; AAD-6222-2021
  • No Thumbnail Available
    Item
    QTc Prolongation During Peripheral Stem Cell Apheresis in Healthy Volunteers
    (2017) Korur, Asli; Kozanoglu, Ilknur; Buyukkurt, Nurhilal; Yeral, Mahmut; Kandemir, Fatih; Gereklioglu, Cigdem; Sariturk, Cagla; Asma, Suheyl; Solmaz, Soner; Boga, Can; Ozdogu, Hakan; 0000-0002-5086-5593; 0000-0001-5335-7976; 0000-0002-8902-1283; 0000-0002-5268-1210; 0000-0002-9580-628X; 0000-0002-4130-1059; 0000-0002-0895-4787; 0000-0002-9680-1958; 27543914; AAD-5616-2021; AAI-7831-2021; AAD-5542-2021; AAD-6222-2021; AAE-1241-2021; ABC-4148-2020; AAS-7129-2021; AAE-1457-2021
    Background and aim: Today, voluntary donation of peripheral blood stem cells by healthy donors for allogeneic hemopoietic cell transplantation is common worldwide. Such donations are associated with small but measurable risks of morbidity and mortality. Most complications are associated with citrate infusion during cell collection. We studied the effects of citrate infusion on the QTc and other vital parameters during and after peripheral stem cell apheresis in volunteers. Method: To ensure that donors were healthy, screening included taking a detailed medical history, physical examination, and laboratory measurements of plasma calcium and magnesium. Corrected QT (QTc) values were assessed using a 12-lead electrocardiographic platform that derived QTc values automatically. Results: In all, 141 apheresis procedures were performed. The mean QTc values at baseline, at 2 and 4 h during the procedure, and at 30 min after the procedure, were 347.6 +/- 59.5, 349.9 +/- 52.8, 391.8 +/- 54.0, and 404.8 +/- 59.2 ms, respectively. The baseline and 2 h QTcs did not differ significantly, but the baseline QTc did differ significantly from the 4 h and 30 min after the procedure values. The plasma levels of calcium and magnesium did not significantly differ before and after the procedure. Conclusion: QTc prolongation may develop during leukopheresis, particularly if the procedure takes more than 2 h. Thus, to enhance donor safety, QTc measurement should be standard for all donors. In addition, any family history of sudden death should be noted, to prevent the development of possible fatal arrhythmia in susceptible donors.
  • No Thumbnail Available
    Item
    Second Malignancies İn Philadelphia-Positive and -Negative Myeloproliferative Neoplasms: A Single Center Study
    (2016) Solmaz, Soner; Korur, Asli; Gereklioglu, Cigdem; Asma, Suheyl; Buyukkurt, Nurhilal; Kasar, Mutlu; Yeral, Mahmut; Kozanoglu, Ilknur; Boga, Can; Ozdogu, Hakan; https://orcid.org/0000-0002-5086-5593; https://orcid.org/0000-0002-0895-4787; https://orcid.org/0000-0003-3856-7005; https://orcid.org/0000-0002-9580-628X; https://orcid.org/0000-0002-8902-1283; AAD-5616-2021; AAE-1457-2021; AAL-3906-2021; ABC-4148-2020; AAD-6222-2021; AAD-5542-2021
    Introduction: Leukemic transformation (LT) of both Philadelphia (Ph) -positive and -negative myeloprolifetarive neoplasms (MPNs) is a well-known subject. However sufficient data are not available in literature from Turkey about the frequency of second malignancies (SMs) except IT in patients with MPNs. In this study, it was aimed to investigate the frequency of SMs in Ph-positive or -negative MPN cases. Materials and Methods: A total of 438 patients diagnosed with classical MPN according to WHO 2008 diagnostic criteria were included in the study. Results: SMs were detected in 15 out of 438 patients (3.4%). In this study, cancer incidence rate was found higher (1149.8/100.000 person-years for males and 540.8/100.000 person-years for females with MPNs) compared with Turkey data. Conclusion: SM frequency is significantly higher than normal population in patients with MPNs. Therefore these patients should be carefully examined for SM symptoms and signs.
  • No Thumbnail Available
    Item
    Red Blood Cell Exchange Followed by Plasma Exchange in Patients with Intrahepatic Cholestasis due to Sickle Cell Disease
    (2016) Buyukkurt, Nurhilal; Kozanoglu, Ilknur; Boga, Can; Ozdogu, Hakan; Yeral, Mahmut; 0000-0002-0895-4787; 0000-0002-5268-1210; 0000-0002-8902-1283; 0000-0002-9580-628X; 0000-0002-9680-1958; AAE-1457-2021; AAE-1241-2021; AAD-6222-2021; AAD-5542-2021; ABC-4148-2020
    Intrahepatic cholestasis, a rare complication of sickle cell anemia, is characterized by marked hyperbilirubinemia, acute hepatic failure, and an often fatal course. In this report, we present patients with homozygous hemoglobin S and one patient with sickle-beta thalassemia disease who have intrahepatic cholestasis. Despite automated red blood cell exchange transfusion, which successfully decreased the hemoglobin S level to less than 30% of total hemoglobin level in the peripheral blood, basic biochemical laboratory examination revealed signs of cholestasis with a serum bilirubin level of up to 50 mg/dL in the first case, 30 mg/dL in the second, and 10 mg/dL in the third. The patients underwent plasma exchange, which improved their clinical condition except one. These cases suggest that plasma exchange may have a role in improving the clinical condition of patients with sickle cell disease complicated with intrahepatic cholestasis (SCIC) that fails to respond to automated red blood cell exchange therapy
  • No Thumbnail Available
    Item
    Quantum Cell Expansion System: Safe and Rapid Expansion
    (2017) Kozanoglu, Ilknur; Maytalman, Erkan; Gereklioglu, Cigdem; Yeral, Mahmut; Buyukkurt, Nurhilal; Aytan, Pelin; Boga, Can; Ozdogu, Hakan; 0000-0002-5268-1210; 0000-0001-5284-7439; 0000-0002-9580-628X; 0000-0002-0895-4787; 0000-0002-2553-7715; 0000-0002-9680-1958; 0000-0002-8902-1283; 28803897; AAE-1241-2021; F-6265-2019; ABC-4148-2020; AAE-1457-2021; AAE-3833-2019; AAD-5542-2021
  • No Thumbnail Available
    Item
    Frequency of Finding Family Donors: A Single Center Experience
    (2018) Kasar, Mutlu; Yeral, Mahmut; Solmaz, Soner; Buyukkurt, Nurhilal; Asma, Suheyl; Gereklioglu, Cigdem; Boga, Can; Ozdogu, Hakan; Basturk, Bilkay; 0000-0003-3856-7005; 0000-0002-9580-628X; 0000-0002-0895-4787; 0000-0001-5335-7976; 0000-0002-8902-1283; 0000-0002-9680-1958; 0000-0002-8784-1974; 29527991; AAL-3906-2021; ABC-4148-2020; AAE-1457-2021; AAI-7831-2021; AAD-6222-2021; AAD-5542-2021; AAD-6918-2021
    Objectives: Allogeneic hematopoietic stem cell transplant is a curative treatment option for many hematologic diseases. The existence of a fully compatible donor for recipients is the first condition for minimized transplant-related mortality and morbidity. The best donor for hematopoietic stem cell transplant is an HLA-matched sibling donor. The possibility of finding an HLA-matched sibling is less than 30% worldwide. Hematopoietic stem cell transplant is needed for an increasing number of patients every year, but the ability to find a fully compatible donor has limited its use. Materials and Methods: From August 2012 to May 2017, we screened 412 adult patients who required AHSCT and their families for HLA tissue groups who were seen at our center (Baskent University Adana Dr. Turgut Noyan Research and Medical Center Hematology Unit). To screen tissue groups at our center, we perform lowresolution typing for HLA-A, B, -C, -DRB1, and -DQB. If an HLA genotype cannot be identified, verification typing is done using high-resolution testing. Results: We found matched family donors in 227 (55%) of 412 patients screened at our center. The ratio of HLAmatched related donors was 83% for 279 patients who received allogeneic stem cell transplant. Conclusions: The likelihood of finding eligible unrelated donors has been gradually increasing, in part due to the development of the National Bone Marrow Bank. However, a careful screening for related donors is still important. Our findings indicate the importance of careful examination of family genealogy and of careful family screening in our region.
  • No Thumbnail Available
    Item
    Survival Outcomes of Young Multiple Myeloma Patients: A Single Center Experience
    (2018) Aytan, Pelin; Yeral, Mahmut; Gereklioglu, Cigdem; Korur, Asli; Tanrikulu, Funda; Solmaz, Soner; Buyukkurt, Nurhilal; Kasar, Mutlu; Asma, Suheyl; Boga, Can; Kozanoglu, Ilknur; Ozdogu, Hakan; AAL-3906-2021; 0000-0002-2553-7715; 0000-0002-9580-628X; 0000-0002-5086-5593; 0000-0002-0895-4787; 0000-0003-3856-7005; 0000-0002-9680-1958; 0000-0002-5268-1210; 0000-0002-8902-1283; AAE-3833-2019; ABC-4148-2020; AAD-5616-2021; AAE-1457-2021; AAD-6222-2021; AAE-1241-2021; AAD-5542-2021
  • No Thumbnail Available
    Item
    Brentuximab Vedotin And Bendamustine: An Effective Salvage Therapy For Relapsed Or Refractory Hodgkin Lymphoma Patients
    (2022) Ulu, Bahar Uncu; Dal, Mehmet Sinan; Hindilerden, Ipek Yonal; Akay, Olga Meltem; Mehtap, Ozgur; Buyukkurt, Nurhilal; Hindilerden, Fehmi; Gunes, Ahmet Kursad; Yigenoglu, Tugce Nur; Basci, Semih; Cakar, Merih Kizil; Acik, Didar Yanardag; Korkmaz, Serdal; Ulas, Turgay; Ozet, Gulsum; Ferhanoglu, Burhan; Nalcaci, Meliha; Altuntas, Fevzi; https://orcid.org/0000-0002-0895-4787; 34514960; AAE-1457-2021
    The prognosis is poor for relapsed or refractory (R/R) classical Hodgkin Lymphoma (cHL) patients. The brentuximab vedotin (Bv) and bendamustine (B) combination has been used as a preferable salvage regimen in R/R cHL patient trials. We retrospectively evaluated response rates, toxicities, and the survival in R/R cHL patients treated with the BvB combination. In a multi-centre real-life study, 61 R/R HL patients received intravenous doses of 1.8 mg/kg Bv on the first day plus 90 mg/m(2) B on the first and second days of a 21-day cycle as a second-line or beyond-salvage regimen. Patients' median age at BvB initiation was 33 (range: 18-76 years). BvB was given as median third-line treatment for a median of four cycles (range: 2-11). The overall and complete response rates were 82% and 68.9%, respectively. After BvB initiation, the median follow-up was 14 months, and one- and two-year overall survival rates were 85% and 72%, respectively. Grade 3/4 toxicities included neutropenia (24.6%), lymphopenia (40%), thrombocytopenia (13%), anaemia (13%), infusion reactions (8.2%), neuropathy (6.5%), and others. The BvB combination could be given as salvage regimen aiming a bridge to autologous stem cell transplant (ASCT), in patients relapse after ASCT or to transplant-ineligible patients with manageable toxicity profiles.
  • No Thumbnail Available
    Item
    Excellent outcomes of allogeneic transplantation from peripheral blood of HLA-matched related donors for adult sickle cell disease with ATLG and posttransplant cyclophosphamide-containing regimen: an update work
    (2020) Ozdogu, Hakan; Boga, Can; Yeral, Mahmut; Kozaoglu, Ilknur; Gereklioglu, Cigdem; Aytan, Pelin; Kasar, Mutlu; Asma, Suheyl; Buyukkurt, Nurhilal; Korur, Asli; Sariturk, Cagla; 0000-0002-0895-4787; 0000-0001-5335-7976; 0000-0002-5086-5593; 0000-0003-3856-7005; 0000-0002-8902-1283; 0000-0002-5268-1210; 0000-0002-9580-628X; 0000-0002-9680-1958; 31992850; AAL-6544-2020; AAE-1457-2021; AAS-7129-2021; ABC-4148-2020; AAI-7831-2021; AAD-5616-2021; AAL-3906-2021; AAD-5542-2021; AAE-1241-2021; AAD-6222-2021
  • No Thumbnail Available
    Item
    Significance of Lymphocyte Count, Monocyte Count, and Lymphocyte-To-Monocyte Ratio in Predicting Molecular Response in Patients with Chronic Myeloid Leukemia: a Single-Centre Experience
    (2020) Pepedil-Tanrikulu, Funda; Buyukkurt, Nurhilal; Korur, Asli; Sariturk, Cagla; Aytan, Pelin; Boga, Can; Ozdogu, Hakan; Kozanoglu, Ilknur; 0000-0002-5268-1210; 0000-0002-0895-4787; 0000-0002-8902-1283; 0000-0002-5086-5593; 0000-0002-9680-1958; 32162884; AAE-1241-2021; AAD-6222-2021; AAE-1457-2021; AAD-5542-2021; AAD-5616-2021
    Background: Chronic myeloid leukemia (CML) is a disease resulting from BCR-ABL gene fusion. It is possible to monitor treatment by molecular testing for BCR-ABL. The lymphocyte-to-monocyte ratio (LMR) is a commonly used marker associated with prognosis in various neoplasms. This study was performed to evaluate the relevance of absolute lymphocyte count (ALC), absolute monocyte count (AMC), and LMR in predicting molecular response status in patients with chronic phase CML. Methods: Samples submitted to our hematology laboratory for BCR-ABL testing between April 2012 and October 2018 were retrospectively reviewed. Concurrent hemogram testing together with the results of quantitative reverse transcriptase-polymerase chain reaction were noted. Data were grouped according to molecular response status and the ALC, AMC, and LMR were compared among patient groups. Results: A total of 224 samples from 95 patients were included in the study. Analysis revealed differences between groups when newly diagnosed patients were compared with patients undergoing treatment, regardless of response status. However, analyzing the groups according to molecular response status failed to reveal differences in ALC, AMC, or LMR. Conclusions: ALC, AMC, and LMR are not potential biomarkers for predicting molecular response status in patients with chronic phase CML.